PL2870160T3 - Inhibitory wirusa zapalenia wątroby typu c - Google Patents

Inhibitory wirusa zapalenia wątroby typu c

Info

Publication number
PL2870160T3
PL2870160T3 PL13739324T PL13739324T PL2870160T3 PL 2870160 T3 PL2870160 T3 PL 2870160T3 PL 13739324 T PL13739324 T PL 13739324T PL 13739324 T PL13739324 T PL 13739324T PL 2870160 T3 PL2870160 T3 PL 2870160T3
Authority
PL
Poland
Prior art keywords
hepatitis
virus
inhibitors
Prior art date
Application number
PL13739324T
Other languages
English (en)
Polish (pl)
Inventor
Kyla Bjornson
Eda Canales
Jeromy J. Cottell
Kapil Kumar Karki
Ashley Anne Katana
Darryl Kato
Tetsuya Kobayashi
John O. Link
Ruben Martinez
Barton W. Phillips
Hyung-Jung Pyun
Michael Sangi
Adam James Schrier
Dustin Siegel
James G. Taylor
Chinh Viet Tran
Martin Teresa Alejandra Trejo
Randall W. Vivian
Zheng-Yu Yang
Jeff Zablocki
Sheila Zipfel
Original Assignee
Gilead Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48803614&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2870160(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.
Publication of PL2870160T3 publication Critical patent/PL2870160T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL13739324T 2012-07-03 2013-07-02 Inhibitory wirusa zapalenia wątroby typu c PL2870160T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261667806P 2012-07-03 2012-07-03
US201361798524P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
PL2870160T3 true PL2870160T3 (pl) 2017-05-31

Family

ID=48803614

Family Applications (2)

Application Number Title Priority Date Filing Date
PL13739324T PL2870160T3 (pl) 2012-07-03 2013-07-02 Inhibitory wirusa zapalenia wątroby typu c
PL16190694T PL3159345T3 (pl) 2012-07-03 2013-07-02 Inhibitory wirusa zapalenia wątroby typu C

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL16190694T PL3159345T3 (pl) 2012-07-03 2013-07-02 Inhibitory wirusa zapalenia wątroby typu C

Country Status (40)

Country Link
US (7) US9296782B2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
EP (4) EP2870160B1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
JP (4) JP6025977B2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
KR (3) KR102040023B1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
CN (2) CN104540832B (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
AP (1) AP3903A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
AR (1) AR091661A1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
AU (6) AU2013286729B2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
BR (2) BR112014033080B1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
CA (1) CA2877005C (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
CL (1) CL2014003634A1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
CO (1) CO7160104A2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
CR (1) CR20150045A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
CY (2) CY1118379T1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
DK (2) DK3159345T3 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
EA (2) EA033961B1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
EC (1) ECSP15002066A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
ES (3) ES2716138T3 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
HR (2) HRP20161379T1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
HU (2) HUE032404T2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
IL (4) IL236500B (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
IN (1) IN2014MN02598A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
LT (2) LT3159345T (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
MD (2) MD4602B1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
ME (2) ME02547B (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
MX (2) MX360597B (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
MY (1) MY173342A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
NZ (2) NZ703064A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
PE (1) PE20150204A1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
PH (3) PH12014502862A1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
PL (2) PL2870160T3 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
PT (2) PT3159345T (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
RS (2) RS58409B1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
SG (3) SG11201408739VA (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
SI (2) SI3159345T1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
SM (3) SMT201600470T1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
TW (1) TWI602822B (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
UA (1) UA119315C2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
UY (1) UY34888A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
WO (1) WO2014008285A1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
HUE031625T2 (en) 2012-10-19 2017-07-28 Bristol Myers Squibb Co 9-methyl substituted hexadecahydrocyclopropa(e)pyrrolo(1,2-a)(1,4)diazacyclopentadecinyl carbamate derivatives as non-structural 3 (ns3) protease inhibitors for the treatment of hepatitis c virus infections
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014071007A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9598433B2 (en) 2012-11-02 2017-03-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014070974A1 (en) 2012-11-05 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
MD4595B1 (ro) 2013-01-31 2018-10-31 Gilead Pharmasset Llc. Tabletă combinată conţinând doi compuşi antivirali
WO2014137869A1 (en) 2013-03-07 2014-09-12 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
CA2902569A1 (en) * 2013-03-15 2014-09-18 Gilead Sciences, Inc. Inhibitors of hepatitis c virus
JP2016529293A (ja) 2013-08-27 2016-09-23 ギリアド ファーマセット エルエルシー ２つの抗ウイルス化合物の組合せ製剤
EP3087086B1 (en) 2013-12-23 2018-11-07 Gilead Sciences, Inc. Crystalline forms of a macrocyclic hcv ns3 inhibiting tripeptide
WO2015100145A1 (en) 2013-12-23 2015-07-02 Gilead Sciences, Inc. Synthesis of a macrocyclic hcv ns3 inhibiting tripeptide
US10059969B1 (en) 2014-10-03 2018-08-28 Abbvie Inc. Process for the preparation of (S)-2-amino-non-8-enoic acid
BR112017013858A2 (pt) 2014-12-26 2018-02-27 Univ Emory n4-hidroxicitidina e derivados e usos antivirais relacionados aos mesmos
US20180050976A1 (en) * 2015-02-16 2018-02-22 Central Glass Company, Limited Practical Processes for Producing Fluorinated alpha-Ketocarboxylic Esters and Analogues Thereof
WO2017184670A2 (en) 2016-04-22 2017-10-26 Gilead Sciences, Inc. Methods for treating zika virus infections
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
ES2989988T3 (es) 2016-05-10 2024-11-28 C4 Therapeutics Inc Degronímeros heterorocíclicos para la degradación de proteínas diana
WO2017197036A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
EP3463469B1 (en) 2016-05-27 2023-12-13 Gilead Sciences, Inc. Combination of ledipasvir and sofosbuvir for use in the treatment of hepatitis b virus infections in humans
BR102017011025A2 (pt) 2016-06-02 2017-12-19 Gilead Pharmasset Llc Formulation of combination of three antiviral compounds
JOP20190052A1 (ar) 2016-09-22 2019-03-21 Astrazeneca Ab 5-[2-(بيريدين-2-يلامينو )-3،1 ثيازول-5-يال]-3،2 – ثنائي هيدرو- 1h- إيزوإندول 1--مشتق واحد واستخدامها كمثبطات مزدوجة للدلتا وغاما فوسفاتيديلينوسيتول 3-كيناز
CA3052039A1 (en) * 2017-02-01 2018-08-09 Abbvie Inc. Enzymatic processes for the preparation of (±)-2-(difluoromethyl)-1-(alkoxycarbonyl)-cyclopropanecarboxylic acid and (±)-2-(vinyl)-1-(alkoxycarbonyl)-cyclopropanecarboxylic acid
EP3641762A4 (en) 2017-06-20 2021-03-10 C4 Therapeutics, Inc. N / O BONDED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION
MX2020005392A (es) 2017-12-07 2020-12-07 Univ Emory N4-hidroxicitidina y derivados y usos antivirales relacionados con los mismos.
CN111018795B (zh) * 2019-12-25 2023-03-28 上海彩迩文生化科技有限公司 一种碱性条件下合成喹喔啉-3-酮的方法
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors
EP4382529A1 (en) 2022-12-07 2024-06-12 Bayer Consumer Care AG A process for preparing pure (3s)-pyrrolidin-3-ol and pure (3s)-pyrrolidin-3-ol hydrochloride

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03005219A (es) 2000-12-12 2003-09-25 Schering Corp Peptidos diarilicos como inhibidores de ns3-serina proteasa en hepatitis de virus c.
BR0213562A (pt) 2001-10-26 2004-08-31 Aventis Pharma Inc Benzimidazóis e análogos e seu uso como inibidores de cinases de proteìna
US6867185B2 (en) 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
WO2004032827A2 (en) 2002-05-20 2004-04-22 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2003099316A1 (en) 2002-05-20 2003-12-04 Bristol-Myers Squibb Company Heterocyclicsulfonamide hepatitis c virus inhibitors
US6878722B2 (en) 2002-05-20 2005-04-12 Bristol-Myers Squibb Company Substituted cycloalkyl P1′ hepatitis C virus inhibitors
ES2386161T3 (es) 2003-04-16 2012-08-10 Bristol-Myers Squibb Company Proceso para separar una mezcla de enantiómeros de éster alquílico usando una enzima
CA2522561C (en) 2003-04-18 2012-07-17 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis c serine protease inhibitors
US7176208B2 (en) 2003-04-18 2007-02-13 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
AU2004240704B9 (en) 2003-05-21 2009-10-22 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor compounds
US7135462B2 (en) 2003-11-20 2006-11-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
DK1778702T3 (da) 2004-07-16 2011-10-17 Gilead Sciences Inc Antivirale forbindelser
WO2007001406A2 (en) 2004-10-05 2007-01-04 Chiron Corporation Aryl-containing macrocyclic compounds
JP4705164B2 (ja) 2005-05-02 2011-06-22 メルク・シャープ・エンド・ドーム・コーポレイション Ｈｃｖｎｓ３プロテアーゼ阻害剤
US7470664B2 (en) 2005-07-20 2008-12-30 Merck & Co., Inc. HCV NS3 protease inhibitors
EP2305695A3 (en) 2005-07-25 2011-07-27 Intermune, Inc. Macrocyclic inhibitors of Hepatitis C virus replication
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
CN101233148A (zh) * 2005-08-01 2008-07-30 默克公司 作为hcv ns3蛋白酶抑制剂的大环肽
CA2615896C (en) * 2005-08-01 2012-11-13 Merck & Co., Inc. Macrocyclic peptides as hcv ns3 protease inhibitors
CA2624333A1 (en) 2005-10-11 2007-04-19 Intermune, Inc. Compounds and methods for inhibiting hepatitis c viral replication
US7772183B2 (en) 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
GB0609492D0 (en) 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
GB0612423D0 (en) 2006-06-23 2006-08-02 Angeletti P Ist Richerche Bio Therapeutic agents
RU2008152171A (ru) 2006-07-05 2010-08-10 Интермьюн, Инк. (Us) Новые ингибиторы вирусной репликации гепатита с
CA2667165A1 (en) 2006-10-24 2008-05-02 Merck & Co., Inc. Hcv ns3 protease inhibitors
AU2007309488B2 (en) 2006-10-24 2012-10-11 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
JP5345541B2 (ja) 2006-10-24 2013-11-20 メルク・シャープ・アンド・ドーム・コーポレーション Ｈｃｖｎｓ３プロテアーゼ阻害剤
JP5352464B2 (ja) 2006-10-27 2013-11-27 メルク・シャープ・アンド・ドーム・コーポレーション Ｈｃｖｎｓ３プロテアーゼ阻害剤
RU2468029C2 (ru) 2006-10-27 2012-11-27 Иституто Ди Ричерке Ди Биолоджиа Молеколаре П.Анджелетти С.П.А. Ингибиторы hcv ns3 протеазы
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20080287449A1 (en) 2007-04-26 2008-11-20 Deqiang Niu Aza-tripeptide hepatitis c serine protease inhibitors
AU2008247509A1 (en) 2007-05-03 2008-11-13 Array Biopharma, Inc. Novel macrocyclic inhibitors of hepatitis C virus replication
EP2185524A1 (en) 2007-05-10 2010-05-19 Intermune, Inc. Novel peptide inhibitors of hepatitis c virus replication
US20090005387A1 (en) 2007-06-26 2009-01-01 Deqiang Niu Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors
AR068794A1 (es) 2007-06-29 2009-12-09 Gilead Sciences Inc Compuestos antivirales
KR101596524B1 (ko) 2007-06-29 2016-02-22 길리애드 사이언시즈, 인코포레이티드 항바이러스 화합물
JP5433573B2 (ja) 2007-07-19 2014-03-05 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ 抗ウイルス剤としての大環状化合物
WO2009014730A1 (en) 2007-07-26 2009-01-29 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
EP2190858A4 (en) 2007-09-24 2013-02-13 Achillion Pharmaceuticals Inc PEPTIDES CONTAINING UREA AS INHIBITORS OF VIRAL REPLICATION
US8106059B2 (en) 2007-10-24 2012-01-31 Virobay, Inc. Substituted pyrazines that inhibit protease cathepsin S and HCV replication
US20090111757A1 (en) 2007-10-25 2009-04-30 Taigen Biotechnology Co., Ltd. Hcv protease inhibitors
CL2008003384A1 (es) 2007-11-14 2009-12-11 Enanta Pharm Inc Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
WO2009070692A1 (en) 2007-11-29 2009-06-04 Enanta Pharmaceuticals, Inc. C5-substituted, proline-derived, macrocyclic hepatitis c serine protease inhibitors
WO2009070689A1 (en) 2007-11-29 2009-06-04 Enanta Pharmaceuticals, Inc. Bicyclic, c5-substituted proline derivatives as inhibitors of the hepatitis c virus ns3 protease
WO2009073719A1 (en) 2007-12-05 2009-06-11 Enanta Pharmaceuticals, Inc. Quinoxalinyl derivatives
US8273709B2 (en) 2007-12-14 2012-09-25 Enanta Pharmaceuticals, Inc. Triazole-containing macrocyclic HCV serine protease inhibitors
US9163061B2 (en) 2007-12-21 2015-10-20 Celgene Avilomics Research, Inc. HCV protease inhibitors and uses thereof
US8293705B2 (en) 2007-12-21 2012-10-23 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
US8309685B2 (en) 2007-12-21 2012-11-13 Celgene Avilomics Research, Inc. HCV protease inhibitors and uses thereof
MX2010008109A (es) 2008-01-24 2010-09-22 Enanta Pharm Inc Tripéptidos difluorizados como inhibidores de proteasa de serina de virus de hepatitis c (hcv).
MX2010008523A (es) 2008-02-04 2010-08-31 Idenix Pharmaceuticals Inc Inhibidores macrociclicos de serina proteasa.
JP5608563B2 (ja) 2008-02-25 2014-10-15 メルク・シャープ・アンド・ドーム・コーポレーション 治療用化合物
WO2009114633A1 (en) 2008-03-12 2009-09-17 Virobay, Inc. Process for the preparation of (3s)-3-amino-n-cyclopropyl-2-hydroxyalkanamide derivatives
MX2010010276A (es) 2008-03-20 2011-03-25 Enanta Pharm Inc Compuestos macrociclicos fluorinados como inhibidores del virus de hepatitis c.
SG175692A1 (en) 2008-04-15 2011-11-28 Intermune Inc Novel macrocyclic inhibitors of hepatitis c virus replication
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2009134624A1 (en) 2008-04-28 2009-11-05 Merck & Co., Inc. Hcv ns3 protease inhibitors
US8211891B2 (en) 2008-04-30 2012-07-03 Enanta Pharmaceuticals, Inc. Difluoromethyl-containing macrocyclic compounds as hepatitis C virus inhibitors
KR101313675B1 (ko) * 2008-07-22 2013-10-02 이스티투토 디 리세르쉐 디 비올로지아 몰레콜라레 피. 안젤레티 에스.알.엘. Ｈｃｖ ｎｓ3 프로테아제 억제제로서의 마크로사이클릭 퀴녹살린 화합물
AU2009278075B2 (en) 2008-08-07 2013-07-04 F. Hoffmann-La Roche Ag Process for the preparation of a macrocycle
US8765667B2 (en) 2008-08-20 2014-07-01 Michael Eissenstat HCV protease inhibitors
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
WO2010033466A1 (en) 2008-09-16 2010-03-25 Phenomix Corporation Macrocyclic inhibitors of hepatitis c protease
EA018603B1 (ru) 2008-09-16 2013-09-30 Бёрингер Ингельхайм Интернациональ Гмбх Кристаллические формы 2-тиазолил-4-хинолинилоксипроизводного, активного ингибитора hcv
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20100080770A1 (en) 2008-09-29 2010-04-01 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
KR20110075019A (ko) 2008-10-15 2011-07-05 인터뮨, 인크. 치료용 항바이러스성 펩티드
WO2010048468A1 (en) 2008-10-23 2010-04-29 Concert Pharmaceuticals, Inc. Deuterated macrocyclic inhibitors of viral ns3 protease
JP5689810B2 (ja) 2008-11-20 2015-03-25 アキリオン ファーマシューティカルズ，インコーポレーテッド Ｃ型肝炎ウイルス用の環状カルボキサミド化合物およびその類似体
WO2010059667A1 (en) 2008-11-21 2010-05-27 Boehringer Ingelheim International Gmbh Pharmaceutical composition of a potent hcv inhibitor for oral administration
US20100272674A1 (en) 2008-12-04 2010-10-28 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
EP2364310B1 (en) 2008-12-10 2015-07-29 Achillion Pharmaceuticals, Inc. 4-amino-4-oxobutanoyl peptide cyclic analogues, inhibitors of viral replication
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2009335904A1 (en) 2008-12-19 2011-08-04 Gilead Sciences, Inc. HCV NS3 protease inhibitors
ES2429013T3 (es) 2008-12-23 2013-11-12 Janssen Pharmaceuticals, Inc. Procedimientos e intermedios para la preparación de un inhibidor macrocíclico de la proteasa de VHC
WO2010132163A1 (en) 2009-05-13 2010-11-18 Enanta Pharmaceuticals, Inc. Macrocyclic compounds as hepatitis c virus inhibitors
WO2010135748A1 (en) 2009-05-22 2010-11-25 Sequoia Pharmaceuticals Inc. Bimacrocyclic hcv ns3 protease inhibitors
EP2459582B1 (en) 2009-07-30 2015-05-27 Merck Sharp & Dohme Corp. Hepatitis c virus ns3 protease inhibitors
UA103807C2 (ru) 2009-07-31 2013-11-25 Кадила Хелткере Лимитед Замещенные бензамидные производные как активаторы глюкокиназы (gk)
US8637449B2 (en) 2009-08-27 2014-01-28 Merck Sharp & Dohme Corp. Processes for preparing protease inhibitors of hepatitis C virus
AU2010298028A1 (en) 2009-09-28 2012-04-19 Intermune, Inc. Cyclic peptide inhibitors of hepatitis C virus replication
TW201116540A (en) 2009-10-01 2011-05-16 Intermune Inc Therapeutic antiviral peptides
TW201119667A (en) 2009-10-19 2011-06-16 Enanta Pharm Inc Bismacrocyclic compounds as hepatitis C virus inhibitors
CN103118681B (zh) 2010-03-10 2015-02-18 艾伯维巴哈马有限公司 固体组合物
US8530497B2 (en) 2010-03-11 2013-09-10 Boehringer Ingelheim International Gmbh Crystalline salts of a potent HCV inhibitor
CA2801584A1 (en) 2010-06-07 2011-12-15 Abbvie Inc. Macrocyclic hepatitis c serine protease inhibitors
WO2012019299A1 (en) 2010-08-11 2012-02-16 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
WO2012037259A1 (en) 2010-09-15 2012-03-22 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
US20130178413A1 (en) 2010-09-21 2013-07-11 John A. McCauley Hcv ns3 protease inhibitors
PE20140015A1 (es) 2010-09-21 2014-02-16 Enanta Pharm Inc Inhibidores de las proteasas de serina del vhc derivados de prolinas macrociclicas
US20120095211A1 (en) 2010-09-22 2012-04-19 Intermune, Inc. Substituted proline inhibitors of hepatitis c virus replication
WO2012047764A1 (en) 2010-10-04 2012-04-12 Intermune, Inc. Therapeutic antiviral peptides
WO2012054874A1 (en) 2010-10-22 2012-04-26 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
CN103328466B (zh) 2010-11-01 2016-08-03 Rfs制药公司 Hcv ns3蛋白酶抑制剂
KR20130143084A (ko) 2010-12-14 2013-12-30 머크 샤프 앤드 돔 코포레이션 마크로락탐의 제조 방법 및 중간체
SG191759A1 (en) 2010-12-30 2013-08-30 Enanta Pharm Inc Phenanthridine macrocyclic hepatitis c serine protease inhibitors
EP2658859A4 (en) 2010-12-30 2014-07-30 Enanta Pharm Inc MACROCYCLIC HEPATITIS C SERIN PROTEASE INHIBITORS
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN103562199B (zh) 2011-05-27 2016-03-30 百时美施贵宝公司 作为丙型肝炎病毒抑制剂的掺入氘的三肽
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8962810B2 (en) 2011-06-16 2015-02-24 AB Pharma Ltd. Macrocyclic heterocyclic compound for inhibiting hepatitis C virus and preparation and use thereof
EP2723337A1 (en) 2011-06-23 2014-04-30 Panmed Ltd. Treatment of hepatitis c virus
BR112014003798A2 (pt) 2011-08-19 2017-03-01 Merck Sharp & Dohme método para fabricar um composto, e, composto
WO2013066753A1 (en) 2011-10-31 2013-05-10 Merck Sharp & Dohme Corp. Compositions useful for the treatment of viral diseases
EP2780026B1 (en) 2011-11-15 2019-10-23 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
AU2013208024A1 (en) 2012-01-12 2014-07-10 Boehringer Ingelheim International Gmbh Stabilized pharmaceutical formulations of a potent HCV inhibitor
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
CA2902569A1 (en) 2013-03-15 2014-09-18 Gilead Sciences, Inc. Inhibitors of hepatitis c virus

Also Published As

Publication number Publication date
MX360597B (es) 2018-11-09
AU2013286729B2 (en) 2015-11-12
KR20160040743A (ko) 2016-04-14
PL3159345T3 (pl) 2019-09-30
EP2870160A1 (en) 2015-05-13
SI3159345T1 (sl) 2019-03-29
PH12014502862B1 (en) 2015-02-23
CA2877005C (en) 2016-12-13
EP2870160B1 (en) 2016-09-28
AU2019222909A1 (en) 2019-09-19
JP2018154651A (ja) 2018-10-04
AU2019222909B2 (en) 2021-03-25
IL261581A (en) 2018-10-31
IL269662A (en) 2019-11-28
SG11201408739VA (en) 2015-01-29
HRP20161379T1 (hr) 2016-12-02
BR112014033080B1 (pt) 2022-03-29
EP3492464A1 (en) 2019-06-05
EA201492214A1 (ru) 2015-10-30
HUE042345T2 (hu) 2019-06-28
KR20150034698A (ko) 2015-04-03
JP2015523365A (ja) 2015-08-13
MD20180040A2 (ro) 2018-11-30
UY34888A (es) 2014-01-31
HK1209416A1 (en) 2016-04-01
HUE032404T2 (en) 2017-09-28
HRP20190578T1 (hr) 2019-05-17
KR102040023B1 (ko) 2019-11-05
MD20140136A2 (ro) 2015-05-31
AU2013286729A1 (en) 2015-01-22
IL236500B (en) 2018-02-28
AU2016200201A1 (en) 2016-02-04
IN2014MN02598A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html) 2015-07-24
CY1118379T1 (el) 2017-06-28
MX2014015846A (es) 2015-08-14
EA027390B1 (ru) 2017-07-31
ME02547B (me) 2017-02-20
TWI602822B (zh) 2017-10-21
AU2016200670A1 (en) 2016-02-25
CN104540832A (zh) 2015-04-22
EP3159345A1 (en) 2017-04-26
AU2017203984A1 (en) 2017-07-06
RS55494B1 (sr) 2017-04-28
AP2014008166A0 (en) 2014-12-31
CN104540832B (zh) 2016-08-24
AR091661A1 (es) 2015-02-18
PE20150204A1 (es) 2015-02-12
EP3492464B1 (en) 2020-08-19
EA201790661A3 (ru) 2017-10-31
CN106117309B (zh) 2019-08-30
IL252446A0 (en) 2017-07-31
US10603318B2 (en) 2020-03-31
AU2021204238A1 (en) 2021-07-22
RS58409B1 (sr) 2019-04-30
US20150175655A1 (en) 2015-06-25
ME03362B (me) 2019-10-20
ECSP15002066A (es) 2015-11-30
MD4602B1 (ro) 2018-11-30
CA2877005A1 (en) 2014-01-09
SMT201900167T1 (it) 2019-05-10
AU2017203984B2 (en) 2019-06-06
CN106117309A (zh) 2016-11-16
US10335409B2 (en) 2019-07-02
IL236500A0 (en) 2015-02-26
DK3159345T3 (en) 2019-03-25
NZ739248A (en) 2019-05-31
SG10201912269YA (en) 2020-02-27
CO7160104A2 (es) 2015-01-15
LT2870160T (lt) 2016-12-12
SMT201600470B (it) 2017-03-08
HK1210151A1 (en) 2016-04-15
ES2716138T3 (es) 2019-06-10
BR122021012378B1 (pt) 2022-05-10
US20160361375A1 (en) 2016-12-15
US9296782B2 (en) 2016-03-29
SMT201600470T1 (it) 2017-03-08
EP3825312A1 (en) 2021-05-26
US9655944B2 (en) 2017-05-23
SG10201702950TA (en) 2017-06-29
NZ703064A (en) 2016-12-23
US20170290827A1 (en) 2017-10-12
KR20190124346A (ko) 2019-11-04
LT3159345T (lt) 2019-03-12
US20190008858A1 (en) 2019-01-10
MY173342A (en) 2020-01-17
BR112014033080A2 (pt) 2017-06-27
JP2020143107A (ja) 2020-09-10
SI2870160T1 (sl) 2016-11-30
WO2014008285A1 (en) 2014-01-09
EA201790661A2 (ru) 2017-08-31
JP6025977B2 (ja) 2016-11-16
US20140017198A1 (en) 2014-01-16
ES2827300T3 (es) 2021-05-20
KR101610575B1 (ko) 2016-04-07
ES2605383T3 (es) 2017-03-14
PH12016502040A1 (en) 2019-02-27
DK2870160T3 (en) 2017-01-23
PT3159345T (pt) 2019-04-15
IL261581B (en) 2019-10-31
PH12020550552A1 (en) 2021-07-26
PT2870160T (pt) 2016-12-12
PH12014502862A1 (en) 2015-02-23
TW201414740A (zh) 2014-04-16
UA119315C2 (uk) 2019-06-10
AP3903A (en) 2016-11-17
JP2016041743A (ja) 2016-03-31
CL2014003634A1 (es) 2015-11-06
US20160130300A1 (en) 2016-05-12
EP3159345B1 (en) 2019-01-09
US20190365748A1 (en) 2019-12-05
CY1121418T1 (el) 2020-05-29
CR20150045A (es) 2015-05-13
EA033961B1 (ru) 2019-12-13
MX2018013668A (es) 2019-01-28

Similar Documents

Publication Publication Date Title
IL269662A (en) Hepatitis C virus inhibitors
IL224369B (en) Combinations of inhibitors for hepatitis c virus
ZA201303752B (en) Inhibitors of hepatitis c virus
ZA201306720B (en) Hepatitis c virus inhibitors
IL221033A0 (en) Hepatitis c virus inhibitors
EP2575819A4 (en) INHIBITORS OF HEPATITIS C VIRUS
IL229270B (en) Hepatitis c virus inhibitors
IL224298A (en) Hepatitis virus inhibitors c
EP2768517A4 (en) HEPATITIS C-VIRUS HEMMER
EP2603080A4 (en) HEPATITIS C-VIRUS HEMMER
ZA201309356B (en) Hepatitis c virus inhibitors
ZA201503458B (en) Hepatitis c virus inhibitors
IL228601A0 (en) Processes for the preparation of hepatitis c virus inhibitors
LT2850075T (lt) Piperazino-piperidino junginiai, kaip hepatito c viruso inhibitoriai